The influence of furosemide on plasma elimination and urinary excretion of drugs in standardbred horses. 1990

A J Stevenson, and M P Weber, and F Todi, and M Mendonca, and J D Fenwick, and E Kwong, and L Young, and R Leavitt, and R Nespolo, and P Beaumier
Race Track Division, Agriculture Canada, Ottawa.

A study of the effects of intravenous administration of either 150 mg or 250 mg of furosemide to standardbred mares pre-treated with other drugs was undertaken to determine whether a unique pattern of drug elimination into urine and from plasma for each compound occurred. Furosemide significantly reduced the plasma concentrations of codeine compared to control 2-6 h after furosemide administration. In contrast, the plasma concentrations of theophylline, phenylbutazone, pentazocine, guaifenesin and flunixin were not markedly altered by furosemide. In the case of acepromazine, clenbuterol and fentanyl, the data generated were insufficient to state with certainty whether or not furosemide affected the plasma concentrations of these three drugs. A significant reduction was noted in the urinary concentrations of guaifenesin, acepromazine, clenbuterol, phenylbutazone, flunixin, fentanyl and pentazocine within 1-4 h of furosemide administration. The urinary concentrations of theophylline remained reduced as long as 8 h after furosemide injection. Furosemide administration to horses pre-treated with codeine resulted in depression of urinary morphine concentrations 2-4 h and 9-12 h after furosemide injection. A lower furosemide dose (150 mg) produced changes in drug urinary excretion and plasma elimination equivalent to the higher dose (250 mg). It is evident that furosemide affects the urinary and plasma concentrations of other co-administered drugs but not in a predictable fashion, which limits the extrapolation of these results to as yet untested drugs.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D009020 Morphine The principal alkaloid in opium and the prototype opiate analgesic and narcotic. Morphine has widespread effects in the central nervous system and on smooth muscle. Morphine Sulfate,Duramorph,MS Contin,Morphia,Morphine Chloride,Morphine Sulfate (2:1), Anhydrous,Morphine Sulfate (2:1), Pentahydrate,Oramorph SR,SDZ 202-250,SDZ202-250,Chloride, Morphine,Contin, MS,SDZ 202 250,SDZ 202250,SDZ202 250,SDZ202250,Sulfate, Morphine
D010423 Pentazocine The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) Fortral,Lexir,Pentazocine Hydrochloride,Pentazocine Lactate,Talwin,Hydrochloride, Pentazocine,Lactate, Pentazocine
D010653 Phenylbutazone A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS. Diphenylbutazone,Fenilbutazon,Butacote,Butadion,Butadione,Butapirazol,Butapyrazole,Butazolidin
D011292 Premedication Preliminary administration of a drug preceding a diagnostic, therapeutic, or surgical procedure. The commonest types of premedication are antibiotics (ANTIBIOTIC PROPHYLAXIS) and anti-anxiety agents. It does not include PREANESTHETIC MEDICATION. Premedications
D002976 Clenbuterol A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma. NAB-365,Planipart,NAB 365,NAB365
D003002 Clonixin Anti-inflammatory analgesic. CBA-93626,Sch-10304,CBA 93626,CBA93626,Sch 10304,Sch10304
D003061 Codeine An opioid analgesic related to MORPHINE but with less potent analgesic properties and mild sedative effects. It also acts centrally to suppress cough. Morphinan-6-ol, 7,8-didehydro-4,5-epoxy-3-methoxy-17-methyl-, (5alpha,6alpha)-,Ardinex,Codeine Phosphate,Isocodeine,N-Methylmorphine,N Methylmorphine
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005082 Physical Exertion Expenditure of energy during PHYSICAL ACTIVITY. Intensity of exertion may be measured by rate of OXYGEN CONSUMPTION; HEAT produced, or HEART RATE. Perceived exertion, a psychological measure of exertion, is included. Physical Effort,Effort, Physical,Efforts, Physical,Exertion, Physical,Exertions, Physical,Physical Efforts,Physical Exertions

Related Publications

A J Stevenson, and M P Weber, and F Todi, and M Mendonca, and J D Fenwick, and E Kwong, and L Young, and R Leavitt, and R Nespolo, and P Beaumier
December 1984, American journal of veterinary research,
A J Stevenson, and M P Weber, and F Todi, and M Mendonca, and J D Fenwick, and E Kwong, and L Young, and R Leavitt, and R Nespolo, and P Beaumier
January 1978, Nephron,
A J Stevenson, and M P Weber, and F Todi, and M Mendonca, and J D Fenwick, and E Kwong, and L Young, and R Leavitt, and R Nespolo, and P Beaumier
June 1990, Journal of clinical pharmacology,
A J Stevenson, and M P Weber, and F Todi, and M Mendonca, and J D Fenwick, and E Kwong, and L Young, and R Leavitt, and R Nespolo, and P Beaumier
January 1990, Drug metabolism and disposition: the biological fate of chemicals,
A J Stevenson, and M P Weber, and F Todi, and M Mendonca, and J D Fenwick, and E Kwong, and L Young, and R Leavitt, and R Nespolo, and P Beaumier
July 1993, Journal of clinical pharmacology,
A J Stevenson, and M P Weber, and F Todi, and M Mendonca, and J D Fenwick, and E Kwong, and L Young, and R Leavitt, and R Nespolo, and P Beaumier
January 1984, Animal blood groups and biochemical genetics,
A J Stevenson, and M P Weber, and F Todi, and M Mendonca, and J D Fenwick, and E Kwong, and L Young, and R Leavitt, and R Nespolo, and P Beaumier
November 1970, Nordisk medicin,
A J Stevenson, and M P Weber, and F Todi, and M Mendonca, and J D Fenwick, and E Kwong, and L Young, and R Leavitt, and R Nespolo, and P Beaumier
July 2000, Metabolism: clinical and experimental,
A J Stevenson, and M P Weber, and F Todi, and M Mendonca, and J D Fenwick, and E Kwong, and L Young, and R Leavitt, and R Nespolo, and P Beaumier
January 1984, Developmental pharmacology and therapeutics,
A J Stevenson, and M P Weber, and F Todi, and M Mendonca, and J D Fenwick, and E Kwong, and L Young, and R Leavitt, and R Nespolo, and P Beaumier
August 1969, Journal of pharmaceutical sciences,
Copied contents to your clipboard!